Research and Development

Showing 15 posts of 9599 posts found.

AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment

November 6, 2023 Research and Development AstraZeneca, CKD, Nephrology, kidney disease, proteinuria

AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the …

AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development

November 1, 2023 Research and Development AstraZeneca, CGT, Pharmacy, cell therapy, cellectis, genomic medicine

AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics …

First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China

October 30, 2023 Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab

Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

October 26, 2023 Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023 Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

GSK shares new data for RSV vaccine Arexvy

October 25, 2023 Research and Development Arexvy, GSK, Immunology, RSV, Vaccine

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …

AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC

October 23, 2023 Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology

AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …

Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment

October 10, 2023 Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion

Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …

First patient dosed in Transgene and BioInvent’s phase 1 trial

October 10, 2023 Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial

Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

October 6, 2023 Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …
diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

October 5, 2023 Research and Development COVID-19, Immunology, Moderna, clinical trial, influenza, vaccines

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and …

Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment

October 3, 2023 Research and Development Acurx Pharmaceuticals, C. difficile, Infections and infestations, clinical trial, infection

Acurx Pharmaceuticals has announced that it has discontinued its phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for …

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023 Research and Development FDA, Invitae, Oncology, cancer testing, oncology

The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the Invitae Common Hereditary Cancers Panel, …

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023 Research and Development AMR, BactiVac, Immunology, vaccines

The University of Birmingham hosted Bacterial Vaccines Network has been awarded £1.4m in funding from the UK government to accelerate …

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023 Research and Development Musculo-skeletal disorder, NMD Pharma, clinical trial, spinal muscular atrophy

NMD Pharma has announced that the first patient has been dosed in its phase 2 clinical trial for its CIC-1 …
The Gateway to Local Adoption Series

Latest content